Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23140183 | 0.87 | PAOX (0.39) | ALDH1A1CHRM1PAOXLMNAMAPT | |
| SCHEMBL11009265 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CHRM1PAOXLMNASLC15A2 | |
| SCHEMBL11009268 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CHRM1PAOXLMNASLC15A2 | |
| SCHEMBL17754227 | 0.77 | KDM4E (0.33) | ALDH1A1FFAR1MAPTCYP19A1RXRA | |
| SCHEMBL9498152 | 0.75 | ALDH1A1 (0.47) | ALDH1A1CHRM1LMNAFFAR1MAPT | |
| SCHEMBL9498159 | 0.75 | ALDH1A1 (0.47) | ALDH1A1CHRM1LMNAFFAR1MAPT | |
| SCHEMBL23140064 | 0.74 | ALDH1A1 (0.42) | ALDH1A1CHRM1PAOXLMNASLC15A2 | |
| SCHEMBL1650009 | 0.73 | ALDH1A1 (0.45) | ALDH1A1PAOXLMNASLC15A2FFAR1 | |
| SCHEMBL1784552 | 0.73 | ALDH1A1 (0.45) | ALDH1A1CHRM1LMNAFFAR1MAPT | |
| SCHEMBL1784553 | 0.73 | ALDH1A1 (0.45) | ALDH1A1CHRM1LMNAFFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | ALDH1A1 2351/4885CHRM1 4560/4885PAOX 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.